Evidence map›Paper›PMID 42589679›Full record

ArticleInternational journal of molecular sciences2026

Co-Mutation of CREBBP/EP300 and POLE/POLD1 Identifies a TMB-High Subset of MSS CRC.

Mariia Gusakova, Fedor Sharko, Eugenia Boulygina, Ksenia Maksimova, Maxim Patrushev

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mariia GusakovaNational Research Center "Kurchatov Institute", 123182 Moscow, Russia.
Fedor SharkoNational Research Center "Kurchatov Institute", 123182 Moscow, Russia.ORCID 0000-0002-1189-5597
Eugenia BoulyginaNational Research Center "Kurchatov Institute", 123182 Moscow, Russia.ORCID 0000-0003-3795-0571
Ksenia MaksimovaNational Research Center "Kurchatov Institute", 123182 Moscow, Russia.
Maxim PatrushevNational Research Center "Kurchatov Institute", 123182 Moscow, Russia.

Funding

Russian Science Foundation 25-25-00739
6 · The paper itself

Abstract

Identifying immunotherapy biomarkers for colorectal cancer (CRC) beyond MSI-high status is challenging. We evaluated CREBBP/EP300 and POLE/POLD1 mutations as candidate markers using public cohorts (MSK-CHORD,

Indexed as

Biomarkers, TumorColorectal NeoplasmsCREB-Binding ProteinE1A-Associated p300 ProteinMutationGene Expression ProfilingHumansBiomarkers, TumorCREB-Binding ProteinCREBBP protein, humanE1A-Associated p300 Proteincolorectal cancerCREBBP/EP300 mutationsimmunotherapyMSSPOLE/POLD1 mutationsTMB-High

Identifiers

PMID42589679
PMCPMC13467031

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.